Caribou Biosciences, Inc. - Common Stock (CRBU)

Caribou Biosciences (NASDAQ:CRBU) Chief Executive Officer Rachel Haurwitz said the company is advancing two CRISPR-enabled, off-the-shelf CAR T cell therapy programs, with its lymphoma candidate vispa-cel now “pivotal-ready” and its multiple myeloma program CB-011 continuing in Phase 1 development.

Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

As of October 2025, the global financial markets are undergoing a profound transformation, driven by an accelerating wave of technological innovation and a pressing global imperative for sustainability. This dynamic landscape is giving rise to several high-growth sectors that are not only reshaping industries but also presenting unprecedented investment opportunities.

Caribou Biosciences reports Q2 2025 earnings with revenue beating estimates at $2.67M but a wider EPS loss of -$0.58. Clinical updates expected in H2 2025.

FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research

RBC's Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming binary catalysts, McCarthy highlights Agios Pharmaceuticals, Caribou Biosciences, and Corbus Pharmaceuticals with key 2024 data readouts and trials.

10x stocks are the holy grail of capital investing. So, here are three companies that have the potential to cross that line.

CRBU stock results show that Caribou Biosciences missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.